



Information within this document is correct as of 16 July 2020.

Our vision: Creating a world in which epidemics are no longer a threat to humanity

Our mission: to stimulate and accelerate the development of vaccines against emerging infectious diseases and enable access to these vaccines for people during outbreaks.

Background

As the COVID-19 pandemic shows, in a world characterised by increasing population density, human mobility, and ecological change, emerging infectious diseases (EIDs) pose a real and growing threat to global health security.

Epidemic diseases affect us all. They do not respect borders. According to the Global Preparedness Monitoring Board report, published September 2019, there is a very real threat of a rapidly moving, highly lethal airborne pandemic killing up to 80 million people in as little as 36 hours and wiping out nearly 5% of the world's economy¹.

No country is prepared for a future outbreak, according to the Global Health Security Index, with many countries lacking essential public health and health system capacities to prevent, detect, and respond to health emergencies². And the costs of EIDs are vast in both human and economic terms. As a result of the COVID-19 pandemic, an estimated US \$ 5.1.2b is being lost to the global economy each month. Even small epidemics can cause tremendous economic disruption.

Vaccines are one of our greatest tools to protect against infectious diseases. The development of vaccines can help save lives, protect societies and restabilise economies. The cost of developing one vaccine candidate for each of the 11 epidemic diseases prioritised by the World Health Organization (WHO) would be around \$ 5.1.2b – less than 40 cents per person globally³.

The creation of CEPI

The global need for an organisation like CEPI was recognised after the devastating West African Ebola epidemic, which killed more than 11,000 people and had an economic and social burden of over 5.1.2b 5.1.2b

The world's response to this crisis fell tragically short. A vaccine that had been under development for more than a decade was not deployed until over a year into the epidemic. That vaccine was shown to be 100% effective, suggesting that much of the epidemic could have been prevented. It was evident that we needed a better system to speed the development of vaccines against known epidemic threats. CEPI was launched at Davos 2017, by the governments of 5.1.2a and 5.1.2a the Bill & Melinda Gates Foundation, the Wellcome Trust, and the World Economic Forum, as the result of a consensus that a coordinated, international, and intergovernmental plan was needed to develop and deploy new vaccines to prevent future epidemics.

¹ apps.who.int/gpmb/assets/annual_report/GPMB_annualreport_2019.pdf

² <https://www.globalhealthnow.org/2019-10/no-country-fully-prepared-high-consequence-infectious-disease-outbreaks>

³ [www.thelancet.com/journals/langlo/article/PIIS2214-109X\(18\)30346-2/fulltext](https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(18)30346-2/fulltext)

⁴ academic.oup.com/jid/article-abstract/218/suppl_5/S698/5129071

To date, CEPI has secured financial support from the Bill & Melinda Gates Foundation, Wellcome Trust, the European Commission, and the governments of [REDACTED] 5.1.2a Additional investment from governments, the private sector and philanthropic foundations has also been provided to support our COVID-19 vaccine programmes (See Page 5).

CEPI is headquartered in [REDACTED] 5.1.2a and has offices in [REDACTED] 5.1.2a
 5.1.2a Our primary governing body is the CEPI Board, with 4 Board Committees: Executive and Investment, Compensation and Nomination, Audit and Risk, and Equitable Access. Our Scientific Advisory Committee is an independent body within our governing structure that provides scientific support, advice, and guidance to the CEPI Board and CEPI Secretariat. Our Joint Coordination Group is a roundtable of independent institutions with an interest in seeing our vaccines successfully developed and deployed in an outbreak.

Filling a critical gap in the vaccine ecosystem

Planning for EIDs is challenging: the R&D is complex, lengthy and expensive. The market potential for such vaccines is limited and testing such vaccines is difficult.

There are already many actors in the “end-to-end space” of vaccine funding and R&D implementation but a number of critical gaps have been identified, which CEPI was designed to fill:

- First, by advancing vaccines against known threats through proof of concept and safety testing in humans and establishing investigational stockpiles before epidemics begin — ‘just in case’.
- Second, by funding new and innovative platform technologies with the potential to accelerate the development and manufacture of vaccines against previously unknown pathogens (eg: 16 weeks from identification of antigen to product release for clinical trials)—‘just in time’.
- Third, by coordinating activities to improve our collective response to epidemics, strengthening capacity in countries at risk, and advancing the regulatory science that governs product development.

CEPI has moved quickly since launch

Since our launch, CEPI has announced six Calls for Proposals (CfP):

- **The first CfP** supports candidate vaccines against MERS-CoV and Nipah and Lassa viruses⁵. These were chosen from a priority list established by the WHO in its *R&D Blueprint*.
- **The second CfP** was launched to advance rapid response platforms against unknown pathogens⁶.
- **CEPI’s third CfP**, issued January 2019, is supporting the development of vaccines against Rift Valley fever and Chikungunya viruses⁷.
- **CEPI’s fourth CfP**, issued October 2019, aims to build upon and expand our second call for the development of rapid response platforms against Disease X. The call seeks to fund multi-purpose platform technologies to advance the development of vaccines and other immunoprophylactics. The call is currently on pause as we focus our resources on our COVID-19 vaccine development efforts and our current vaccine portfolio.
- **CEPI’s fifth CfP** issued in early February 2020, invited funding applications for proven vaccine technology that could be used to rapidly develop a vaccine against the new coronavirus, and most importantly at scale and with the necessary equitable access provisions.

⁵ cepi.net/get_involved/cfps/

⁶ cepi.net/get_involved/cfps/

⁷ cepi.net/get_involved/cfps/

- CEPI's sixth Cfp invited organisations around the world to apply for funding to speed up the development, scale-up manufacturing capacity, and expand the geographical footprint of production of COVID-19 vaccine candidates. This call is currently closed. An updated call will be published in the coming weeks.

CEPI partner	Vaccine	Funding
Clover Biopharmaceuticals Australia	COVID-19	5.1.2b
Colorado State University	Rift Valley Fever	
CureVac	RNA platform (Rabies, Yellow fever, Lassa)	
CureVac	COVID-19	
Emergent Biosolutions & PATH	Lassa	
IAVI	Lassa	
IDT Biologika	MERS	
Imperial College London	saRNA platform (Rabies, Marburg, Flu)	
Inovio pharmaceuticals	Lassa & MERS	
Inovio pharmaceuticals	COVID-19	
Institut Pasteur (Themis, University of Pittsburgh)	COVID-19	
Janssen Vaccines & University of Oxford	Lassa, MERS, & Nipah	
Moderna, Inc.	COVID-19	
Novavax Inc.	COVID-19	
Profectus Biosciences, Emergent Biosolutions, & PATH	Nipah	
Public Health Vaccines	Nipah	
Themis Bioscience	Lassa & MERS	
Themis Bioscience	Chikungunya	
University of Queensland	Molecular clamp platform (Rabies, Yellow fever, Lassa)	
University of Queensland and CSL	COVID-19	
University of Oxford and AstraZeneca	COVID-19	
University of Hong Kong	COVID-19	
University of Tokyo	Nipah	
Valneva SE	Chikungunya	
Wageningen Bioveterinary Research	Rift Valley Fever	

CEPI's work on Ebola

CEPI is working to 'finish the job on Ebola' and aims to achieve the overall goal of attaining licensure for two or more Ebola vaccines.

Roll-out of a second Ebola vaccine, manufactured by Johnson & Johnson, began mid-November in the 5.1.2a CEPI was part of a global consortium supporting the Government of the 5.1.2a to introduce a second investigational Ebola vaccine.

The outbreak was declared over on 24 June 2020. There had been over **3400 cases** of Ebola in the epidemic with **2279 deaths**, making this the second worst Ebola outbreak in history.

CEPI is also part of a collaboration which launched a two-year clinical trial of the vaccine among healthcare and frontline workers in 5.1.2a in 2019.

CEPI's work on COVID-19

The spread of COVID-19 has become a humanitarian and economic crisis. Scientific innovations – the rapid development and deployment of vaccines, as well as therapeutics and diagnostics are our exit strategy. No other single measure will have a similar impact on the world's ability to respond to this threat.

CEPI moved quickly and urgently to coordinate with the World Health Organization (WHO), global health authorities and other partners to rapidly develop vaccine candidates against the disease. CEPI's COVID-19 portfolio has been built of the principles of **Speed, Scale, and Access**.

We have so far deployed up to US \$ 5.1.2b in the search for a COVID-19 vaccines, through 9 partnerships with: [Inovio](#), [University of Queensland and CSL](#), [CureVac](#), [Moderna Inc.](#), and the [U.S. National Institute of Allergy and Infectious Diseases](#), [Novavax](#), [University of Oxford and AstraZeneca](#), a consortium led by [Institut Pasteur and including Themis Bioscience and the University of Pittsburgh](#), [Clover Biopharmaceuticals](#) and [The University of Hong Kong](#). [GSK](#) will also provide its established pandemic vaccine adjuvant platform technology to CEPI partners to enhance the development of a vaccine.

In as little as 6 months from publication of the virus's genetic sequence, 7 of our partners have entered clinical trials (Moderna, Inovio, University of Oxford and AstraZeneca, Novavax, CureVac, Clover BioPharmaceuticals and University of Queensland) have entered clinical trials.

Through COVAX, the vaccines pillar of the ACT Accelerator launched in partnership with Gavi and the World Health Organization (WHO), our ultimate goal is to provide an end-to-end solution to develop, manufacture and equitably deliver up to 5.1.1c doses of vaccine by the end of 2021, saving millions of lives and transforming the economic prospects of societies around the world.

To achieve this goal, CEPI is expanding and diversifying its portfolio to increase our chances of finding a successful vaccine which can be manufactured at scale. Work is ongoing to develop a global mechanism to procure and fairly allocate COVID-19 vaccines (COVAX Facility).

The Governments of 5.1.2a, 5.1.2a, the Netherlands, 5.1.2a alongside private sector companies and donations through the UN Foundation COVID-19 Solidarity Response Fund, have pledged financial contributions \$ 5.1.2b to support our efforts. Confirmed donations to support CEPI's COVID-19 efforts are listed in the below table.

INVESTOR	FUNDING (USD)
SOVEREIGN GOVERNMENTS	
5.1.2a	5.1.2b

5.1.2a		
5.1.2e		5.1.2e 5.1.2b
Netherlands		
5.1.2a		
PRIVATE SECTOR		
ADX Labs		5.1.2b
Sumitomo Mutsui Banking Corporation		
Avast		
Partners of Citadel		
Nestle		
Derwent London		
Duff & Phelps Charitable Foundation		
General Catalyst		
Goldman Sachs Gives		
Lululemon		
Ndemic		
TPG Global		
Weplay		
Danske Bank Foundation		
A Collected Man		
Beiersdorf		
OTHER		
UN Foundation COVID-19 Solidarity Response Fund		5.1.2b
Individual philanthropic donations		

An opportunity for leadership in the world

CEPI offers a unique opportunity for our investors to lead on global health security and, in partnership with other governments and international organisations, invest in a solution that protects some of the most vulnerable people in the world while helping to halt the spread of COVID-19 and other emerging infectious diseases. Without immediate additional financial contributions the vaccine programmes we have begun will not be able to progress and ultimately will not deliver the vaccines that the world needs. **Sign up to our newsletter www.cepi.net | Follow us on [Twitter](#) and [LinkedIn](#) | Watch our [video](#) |**